Stifel raised the firm's price target on RH to $130 from $110 and keeps a Hold rating on the shares. Q1 results outperformed expectations, eclipsing the high end of the company's guidance with RH increasing the low end of FY26 revenue and EBITDA guidance, notes the analyst, who cites higher prevailing multiples for the firm's raised target.
